NASDAQ:VBIV

VBI Vaccines - VBIV Stock Forecast, Price & News

$0.30

+0.01 (+5.15%)

(As of 03/27/2023 05:26 PM ET)

Add

Compare

Today's Range: $0.28
▼
$0.31
50-Day Range: $0.29
▼
$0.64
52-Week Range: $0.24
▼
$1.86

Volume: 867,464 shs
Average Volume: 896,686 shs
Market Capitalization: $77.58 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $2.00

Institutional Ownership

VBI Vaccines MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 565.8% Upside
$2.00 Price Target
Short Interest: Bearish
6.18% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.75
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.28) to ($0.20) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.83 out of 5 stars

Medical Sector

801st out of 995 stocks

Pharmaceutical Preparations Industry

390th out of 482 stocks

3.5

Analyst's Opinion

Consensus Rating
VBI Vaccines has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $2.00, VBI Vaccines has a forecasted upside of 565.8% from its current price of $0.30.
Amount of Analyst Coverage
VBI Vaccines has received no research coverage in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
6.18% of the float of VBI Vaccines has been sold short.
Short Interest Ratio / Days to Cover
VBI Vaccines has a short interest ratio ("days to cover") of 16.2, which indicates bearish sentiment.
Change versus previous month
Short interest in VBI Vaccines has recently increased by 8.74%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
VBI Vaccines does not currently pay a dividend.
Dividend Growth
VBI Vaccines does not have a long track record of dividend growth.

3.9

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
VBI Vaccines has received a 51.81% net impact score from Upright. VBI Vaccines seems to create the most significant positive value in categories "Jobs", "Creating knowledge", and "Physical diseases". The positive contribution in the "Creating knowledge" impact category is false driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for VBI Vaccines is -0.75.

2.7

News and Social Media Coverage

News Sentiment
VBI Vaccines has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for VBI Vaccines this week, compared to 1 article on an average week.
Search Interest
Only 17 people have searched for VBIV on MarketBeat in the last 30 days. This is a decrease of -56% compared to the previous 30 days.
MarketBeat Follows
Only 5 people have added VBI Vaccines to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, VBI Vaccines insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 9.50% of the stock of VBI Vaccines is held by insiders.
Percentage Held by Institutions
Only 38.24% of the stock of VBI Vaccines is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for VBI Vaccines are expected to grow in the coming year, from ($0.28) to ($0.20) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of VBI Vaccines is -0.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of VBI Vaccines is -0.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
VBI Vaccines has a P/B Ratio of 1.20. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About VBI Vaccines (NASDAQ:VBIV) Stock

VBI Vaccines, Inc. is a biopharmaceutical company, which engages in the development of infectious disease and immuno-oncology vaccines. The firm focuses on the prevention and treatment of hepatitis B through its product pipeline, Sci-B-Vac and VBI-2601. It also develops an enveloped virus-like particle (eVLP) platform technology, which allows the development of eVLP vaccines that closely mimic the target virus to elicit a potent immune response. The company was founded on April 9, 1965 and is headquartered in Cambridge, MA.

Receive VBIV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for VBI Vaccines and its competitors with MarketBeat's FREE daily newsletter.

VBIV Stock News Headlines

March 18, 2023 | americanbankingnews.com

Analysts Offer Predictions for VBI Vaccines Inc.'s Q4 2023 Earnings (NASDAQ:VBIV)

March 17, 2023 | americanbankingnews.com

VBI Vaccines Inc. (NASDAQ:VBIV) Expected to Earn Q1 2023 Earnings of ($0.07) Per Share

March 27, 2023 | Investor Place Media (Ad)

Biden To Unleash "Choke Point" Operation On America?

Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.

March 15, 2023 | msn.com

VBI Vaccines Earnings Perspective: Return On Capital Employed

March 15, 2023 | finance.yahoo.com

VBI Vaccines Full Year 2022 Earnings: Revenues Beat Expectations, EPS Lags

March 13, 2023 | finance.yahoo.com

VBI Vaccines Reports Full Year 2022 Financial Results

February 24, 2023 | usatoday.com

Mpox vaccine worked well, safely, CDC data shows. Committee votes to continue its use.

February 24, 2023 | abcnews.go.com

Flu vaccine worked well in season that faded fast, CDC says

March 27, 2023 | Behind the Markets (Ad)

[BREAKING] New "Living Missile" to Replace Nuclear Missiles

CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!

February 24, 2023 | cnn.com

CDC advisers vote in favor of using mpox vaccine in future outbreaks

February 24, 2023 | nypost.com

First-ever RSV vaccine could be approved, roll out by August

February 23, 2023 | finance.yahoo.com

VBI Vaccines to Discuss Progress in Hepatitis B Portfolio in Analyst-Led Fireside Chat

February 21, 2023 | forbes.com

First FDA-Approved RSV Vaccines Expected Later This Year: The Top Vaccines And Their Effectiveness

February 20, 2023 | usnews.com

Moderna Bows to Pressure, Says COVID-19 Vaccines Will Remain Free After Emergency Ends

February 15, 2023 | finance.yahoo.com

VBI Vaccines Announces Presentation of Interim Phase 2 Data Evaluating Combination of VBI-2601 (BRII-179) and BRII-835 for the Treatment of Chronic Hepatitis B

January 24, 2023 | finance.yahoo.com

Individual investors account for 55% of VBI Vaccines Inc.'s (NASDAQ:VBIV) ownership, while private equity firms account for 25%

January 23, 2023 | nypost.com

COVID vaccine may make Botox less effective: study

January 16, 2023 | abcnews.go.com

Companies look at increasing price of their COVID-19 vaccines. Bernie Sanders is not happy

January 12, 2023 | cnet.com

First Ever Honeybee Vaccine Approved to Target Deadly Global Disease

January 12, 2023 | nbcnews.com

A fake tweet spurred an anti-vaccine harassment campaign against a doctor

January 3, 2023 | usatoday.com

Fact check: Post falsely claims that FDA said Pfizer vaccines cause blood clots

December 17, 2022 | seekingalpha.com

VBIV VBI Vaccines Inc.

December 8, 2022 | finance.yahoo.com

VBI Vaccines Announces Health Canada Approval for PreHevbrio™ for the Prevention of Hepatitis B in Adults

December 6, 2022 | finance.yahoo.com

CEPI Boosts ‘Coronavirus X’ Vaccine Search With Expanded VBI Vaccines Deal

November 22, 2022 | finance.yahoo.com

VBI Vaccines Presents Additional Phase 1/2a Data from VBI-1901 in Recurrent GBM at the 2022 Society for Neuro-Oncology (SNO) Annual Meeting

November 11, 2022 | finance.yahoo.com

VBI Vaccines Announces Presentation of Data from Ongoing Phase 2a Study of VBI-1901 at the 2022 Society for Neuro-Oncology (SNO) Annual Meeting

November 4, 2022 | finance.yahoo.com

Adaptive Biotechnologies (ADPT) Reports Q3 Loss, Lags Revenue Estimates

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive VBIV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for VBI Vaccines and its competitors with MarketBeat's FREE daily newsletter.

VBIV Company Calendar

Last Earnings: 3/13/2023
Today: 3/27/2023
Next Earnings (Estimated): 5/08/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:VBIV
CUSIP: N/A
CIK: 764195
Web: www.vbivaccines.com
Phone: (617) 830-3031
Fax: N/A
Employees: 149
Year Founded: 2001

Price Target and Rating

Average Stock Price Forecast: $2.00
High Stock Price Forecast: $2.00
Low Stock Price Forecast: $2.00
Forecasted Upside/Downside: +565.8%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.44)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-113,300,000.00
Net Margins: -10,471.63%
Pretax Margin: -10,471.63%
Return on Equity: -115.47%
Return on Assets: -63.81%

Debt

Debt-to-Equity Ratio: 0.76
Current Ratio: 2.10
Quick Ratio: 1.92

Sales & Book Value

Annual Sales: $1.08 million
Price / Sales: 71.83
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.25 per share
Price / Book: 1.20

Miscellaneous

Outstanding Shares: 258,260,000
Free Float: 233,723,000
Market Cap: $77.58 million
Optionable: Optionable
Beta: 1.92

Social Links

Key Executives

Jeff Baxter
President, Chief Executive Officer & Director

Christopher McNulty
CFO, Director & Head-Business Development

Francisco Diaz-Mitoma
Chief Medical Officer

David Evander Anderson
Chief Scientific Officer

T. Adam Buckley
Senior Vice President-Business Development

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

VBIV Stock - Frequently Asked Questions

Should I buy or sell VBI Vaccines stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for VBI Vaccines in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" VBIV shares.
View VBIV analyst ratings or view top-rated stocks.
What is VBI Vaccines' stock price forecast for 2023?: 1 analysts have issued 12-month price objectives for VBI Vaccines' stock. Their VBIV share price forecasts range from $2.00 to $2.00. On average, they predict the company's stock price to reach $2.00 in the next year. This suggests a possible upside of 565.8% from the stock's current price.
View analysts price targets for VBIV or view top-rated stocks among Wall Street analysts.
How have VBIV shares performed in 2023?: VBI Vaccines' stock was trading at $0.3911 at the beginning of the year. Since then, VBIV shares have decreased by 23.2% and is now trading at $0.3004.
View the best growth stocks for 2023 here.
When is VBI Vaccines' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 8th 2023.
View our VBIV earnings forecast.
How were VBI Vaccines' earnings last quarter?: VBI Vaccines Inc. (NASDAQ:VBIV) posted its quarterly earnings results on Monday, March, 13th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by $0.01. The biopharmaceutical company earned $0.29 million during the quarter, compared to analysts' expectations of $1.98 million. VBI Vaccines had a negative trailing twelve-month return on equity of 115.47% and a negative net margin of 10,471.63%.
What ETF holds VBI Vaccines' stock ?: ETFMG Treatments Testing and Advancements ETF holds 56,036 shares of VBIV stock, representing 0.12% of its portfolio.

What other stocks do shareholders of VBI Vaccines own?: Based on aggregate information from My MarketBeat watchlists, some companies that other VBI Vaccines investors own include BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities (), Sterne Agee CRT (), Robert W. Baird (), Wellington Shields () and Macquarie ().
What is VBI Vaccines' stock symbol?: VBI Vaccines trades on the NASDAQ under the ticker symbol "VBIV."
Who are VBI Vaccines' major shareholders?: VBI Vaccines' stock is owned by a number of retail and institutional investors. Top institutional investors include Cambridge Investment Research Advisors Inc. (1.29%), Charles Schwab Investment Management Inc. (0.57%), Renaissance Technologies LLC (0.27%), Captrust Financial Advisors (0.21%), Millennium Management LLC (0.15%) and Deutsche Bank AG (0.11%). Insiders that own company stock include Life Sciences Maste Perceptive, Nell Beattie and Perceptive Advisors Llc.
View institutional ownership trends.
How do I buy shares of VBI Vaccines?: Shares of VBIV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is VBI Vaccines' stock price today?: One share of VBIV stock can currently be purchased for approximately $0.30.
How much money does VBI Vaccines make?: VBI Vaccines (NASDAQ:VBIV) has a market capitalization of $77.58 million and generates $1.08 million in revenue each year. The biopharmaceutical company earns $-113,300,000.00 in net income (profit) each year or ($0.44) on an earnings per share basis.
How many employees does VBI Vaccines have?: The company employs 149 workers across the globe.
How can I contact VBI Vaccines?: VBI Vaccines' mailing address is 222 Third Street Suite 2241, Cambridge MA, 02142. The official website for the company is www.vbivaccines.com. The biopharmaceutical company can be reached via phone at (617) 830-3031 or via email at ir@vbivaccines.com.

This page (NASDAQ:VBIV) was last updated on 3/27/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

VBI Vaccines - VBIV Stock Forecast, Price & News

VBI Vaccines MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About VBI Vaccines (NASDAQ:VBIV) Stock

VBIV Stock News Headlines

VBIV Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Institutional Ownership

VBIV Stock - Frequently Asked Questions

Overall MarketRank^™